Syncona: Achilles Announces Sale Of Technology Assets To AstraZeneca - Quick Facts

(RTTNews) - Syncona said its investment Achilles Therapeutics has announced the sale of technology assets to AstraZeneca. The transaction include transferring of the commercial license of data and samples from the TRACERx non-small cell lung cancer study to AstraZeneca. AstraZene https://www.nasdaq.com/articles/syncona-achilles-announces-sale-technology-assets-astrazeneca-quick-facts